Cancer statistics for African Americans, 1996

Wingo, Phyllis A.; Bolden, Sherry; Tong, Tony; Parker, Sheryl L.; Martin, Linda; Heath, Clark W.

doi:10.3322/canjclin.46.2.113

Cited by 84 publications

(35 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Racial and ethnic differences in treatment and survival have been previously reported for several gynecologic malignancies, including ovary and uterine cancers (Wingo et al, 1996;Madison et al, 1998;Maxwell et al, 2006;Morris et al, 2006;Chan et al, 2008). In uterine sarcomas, Brooks et al (2004) found a survival difference among racial groups, but this was no longer present after adjusting for treatment differences.…”

Section: Discussionmentioning

confidence: 85%

Endometrial stromal sarcoma: a population-based analysis

et al. 2008

View full text Add to dashboard Cite

To determine independent prognostic factors for the survival of patients with endometrial stromal sarcoma (ESS), data were abstracted from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute from 1988 to 2003. Kaplan -Meier and Cox proportional hazards models were used for analyses. Of 831 women diagnosed with ESS, the median age was 52 years (range: 17 -96 years). In total, 59.9% had stage I, 5.1% stage II, 14.9% stage III, and 20.1% had stage IV disease. Overall, 13.0, 36.1, and 34.7% presented with grades 1, 2, and 3, respectively. Patients with stage I-II vs III-IV disease had 5 years DSS of 89.3% vs 50.3% (Po0.001) and those with grades 1, 2, and 3 cancers had survivals of 91.4, 95.4, and 42.1% (Po0.001). In multivariate analysis, older patients, black race, advanced stage, higher grade, lack of primary surgery, and nodal metastasis were independent prognostic factors for poorer survival. In younger women (o50 years) with stage I -II disease, ovarian-sparing procedures did not adversely impact survival (91.9 vs 96.2%; P ¼ 0.1). Age, race, primary surgery, stage, and grade are important prognostic factors for ESS. Excellent survival in patients with grade 1 and 2 disease of all stages supports the concept that these tumors are significantly different from grade 3 tumors. Ovarian-sparing surgeries may be considered in younger patients with early-stage disease.

show abstract

Section: Discussionmentioning

confidence: 85%

Endometrial stromal sarcoma: a population-based analysis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Studies conducted in NorthAmerican population showed a high incidence of prostate cancer in Blacks, with a low incidence in Whites (12)(13)(14).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of prostate adenocarcinoma according to race in an university hospital

et al. 2003

View full text Add to dashboard Cite

Objectives: To determine the prevalence of prostate cancer and to assess potential associations between race and prostate adenocarcinoma according to age in patients followed in an outpatient service of general urology in an university hospital.Materials and Methods: Retrospective study of men aged from 40 to 79 years, followed during the period from 1999 to 2001. Patients were classified according to race in White, Mulatto and Black. Those with abnormal digital rectal examination and/or serum level of prostate specific antigen (PSA) > 4.0 ng/ml, underwent a transrectal prostate biopsy.Results: 580 patients with mean age of 60.7 ± 10.0 years were studied, with 116 Whites (20.0%), 276 Mulattos (47.6%) and 188 Blacks (32.4%). There was no significant difference regarding the mean age (p = 0.62), serum level of PSA (p = 0.65) and prevalence of prostate adenocarcinoma between Whites, Mulattos and Blacks (p = 0.36). While studying the association between race classified in 2 groups (Whites versus Mulattos and Blacks) and prostate adenocarcinoma according to age, no association was found when the total group was assessed, neither among those with age above 60 years old. In the group between 40 and 60 years, even though without statistical significance, the estimate of prevalence ratio was 2.2 (CI 95%: 0.52 to 9.0; p = 0.38).Conclusion: Prostate adenocarcinoma was found in 16.6% of the patients aged between 40 and 79 years. We did not find a racial influence in our population.

show abstract

“…Although research suggests that one out of every 6 African American men will develop prostate cancer in his lifetime (Wingo et al, 1996), many investigators have reported that African American men are the least likely to participate in prostate cancer screening and regular check ups (see for example, Catalona et al, 1994). This low rate of participation in prostate cancer screening suggests that African American men present their diseases at more advanced stages, and thereby also increase their mortality rate from the disease.…”

Section: Introductionmentioning

confidence: 99%

Changing the Attitudes and Behaviors of Black Men to Screening for Prostate Cancer

Twum¹

2005

View full text Add to dashboard Cite

Cancer statistics for African Americans, 1996

Cited by 84 publications

References 7 publications

Endometrial stromal sarcoma: a population-based analysis

Endometrial stromal sarcoma: a population-based analysis

Prevalence of prostate adenocarcinoma according to race in an university hospital

Changing the Attitudes and Behaviors of Black Men to Screening for Prostate Cancer

Contact Info

Product

Resources

About